Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2014; 20(2): 486-497
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.486
Published online Jan 14, 2014. doi: 10.3748/wjg.v20.i2.486
Table 2 Ongoing clinical studies that analyzed targeted therapy in combination with radiofrequency ablation
Number of clinical trials | Phase | Drug | Patients (n) | Timing | Primary endpoint |
NCT01470495 | Randomized study | Sorafenib (dose non specified) | 200 TR | Together with RFA continuously | TTP |
NCT00813293 | II | Sorafenib (800 mg/d) | 20 | 9 d before RFA | Effectiveness |
SORAMIC trial | II | Sorafenib (dose non specified) | 1500 | After RFA or SIRT | Time to recurrence, OS |
NCT01126645 | |||||
STORM trial NCT00692770 | III | Sorafenib(800 mg/d) | 1114 | After RFA continuously | RFS |
NCT00728078 | II-III | Thalidomide (150 mg/d) | 200 | After RFA for 6 mo | PFS, morbidity |
- Citation: Ranieri G, Marech I, Lorusso V, Goffredo V, Paradiso A, Ribatti D, Gadaleta CD. Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment. World J Gastroenterol 2014; 20(2): 486-497
- URL: https://www.wjgnet.com/1007-9327/full/v20/i2/486.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i2.486